WO2011150513A1 - Carbanucleoside synthesis and novel intermediate compounds useful therein - Google Patents
Carbanucleoside synthesis and novel intermediate compounds useful therein Download PDFInfo
- Publication number
- WO2011150513A1 WO2011150513A1 PCT/CA2011/050324 CA2011050324W WO2011150513A1 WO 2011150513 A1 WO2011150513 A1 WO 2011150513A1 CA 2011050324 W CA2011050324 W CA 2011050324W WO 2011150513 A1 WO2011150513 A1 WO 2011150513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- protected
- carbanucleoside
- Prior art date
Links
- 0 *[C@@](C[C@]([C@@]1CO)O)C1=C Chemical compound *[C@@](C[C@]([C@@]1CO)O)C1=C 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to processes and intermediates for use in preparing anti-viral compounds. More particularly, it relates to chemical synthesis of anti-viral carbanucleoside compounds having a cyclopentanol ring bonded to a nitrogen heterocycle such as a purine or pyrimidinone, as exemplified by entacavir (2-amino-1 ,9-dihydro-9-((1 S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2- methylenecyclopentyl)-28 6H-purin-6-one), and intermediates useful in such synthesis.
- entacavir 2-amino-1 ,9-dihydro-9-((1 S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2- methylenecyclopentyl)-28 6H-purin-6-one
- Baraclude is an anti-virally active pharmaceutical compound used in the treatment of hepatitis B infections in humans. It is marketed under the trade name “Baraclude”, as oral tablets and solutions.
- Prior art methods of making entecavir involve protection of hydroxyl and hydroxymethyl groups on a cyclopentane starting material with silyl protectant groups, while chemical reaction and derivatization of other groups to form the entecavir molecule are conducted.
- the silyl protectant groups are removed by hydrolysis in a final or close to final synthetic process step.
- the present invention provides a synthesis of entecavir and similar carbanucleoside compounds, which avoids the use of silyl protectant groups. Instead, the hydroxyl group and hydroxymethyl group on adjacent carbon atoms of the cyclopentane ring are protected with an alkyl aromatic group.
- the aromatic group phenyl, naphthyl and the like
- the intermediate compounds carrying the aromatic protectant are almost all solid and crystalline, allowing purification of them by simple crystallization.
- R represents a nitrogen heterocycle selected from purine, adenine, guanine, uracil, thymidine, cytosine and substituted derivatives thereof, which includes the steps of reacting a protected cyclopentanol of formula:
- Ar is an aromatic nucleus, with an appropriately protected purine, adenine, guanine, uracil, thymidine, cytosine or substituted derivative thereof, and subsequently deprotecting the resultant carbanucleoside to produce a compound of formula I.
- group Ar is phenyl, on account of the fact that such intermediate can be prepared from the readily available starting materials, Corey lactone diol of formula 1 on the accompanying Figure of the drawings and benzaldehyde dimethyl acetal. Analogous materials having other aromatic groups such as inertly substituted phenyl naphthyl and the like can be synthesized and used, if desired, provided that any such substituents do not interfere with the subsequent reactions.
- the first reaction step in the preferred process according to the invention is the reaction of Corey lactone diol with benzaldehyde dimethyl acetal to form the ring protected diol 2 shown on the accompanying drawing.
- This is suitably accomplished in an inert aromatic solvent such as toluene, under reflux, with removal of the methanol so formed.
- the product 2 is a solid which can be filtered off and purified by simple washing.
- the protected diol 2 is reduced to a lactol 3. This can be done with an organometallic reducing agent such as dibutylaluminum hydride, DIBAL, in solution at low temperatures, suitably below -20°C. Again the product 3 is a solid, obtainable by evaporation of the product solution to dryness. Purification of lactol 3 prior to the next reaction step is unnecessary.
- a vinyl ether reaction of compound 3 with methanesulfonyl chloride in the presence of triethylamine, at similar low temperatures is preferred.
- Tetrahydrofuran is a suitable solvent, and the methanesulfonyl chloride is best added dropwise to the reaction mixture.
- the resultant vinyl ether is a solid, which can be recovered by filtration and washed for purification purposes.
- the vinyl ether 4 is then converted to a diol 5, by oxidation in solution with, e.g., 3-chloroperbenzoic acid or the like, at temperatures around 0°C. Again, THF is a suitable solvent.
- the cyclopentane diol so formed is a solid material, recoverable by filtration, and can be purified to a satisfactory degree by simple washing, ready to proceed to the next step.
- the diol 5 is converted to aldehyde, compound 6 on Fig. 1 , by ring opening oxidation using a strong oxidizing agent such as sodium periodate.
- a strong oxidizing agent such as sodium periodate.
- a mixture of THF and water is suitable as a solvent, with the product 6, which again is a solid, dissolving in the organic layer. It can be recovered from the separated organic layer by concentration and filtration. Further purification prior to the next reaction step is unnecessary.
- the next reaction step is the reduction of the aldehyde 6 to form the cyclopentane diol 7.
- a suitable reducing agent for this purpose is sodium borohydride, again in THF solvent.
- the product is solid, recoverable by filtration, to be washed and dried before the next step of the procedure.
- Tosyl is the preferred protectant group for the hydroxymethyl group, so that the next step in the preferred reaction sequence is reaction of compound 7 with p- toluenesulfonic acid or a halide thereof in pyridine-dichloromethane solvent.
- acetic anhydride in pyridine can be added to the reaction mixture, and the tosyl acetate compound 8 formed. After concentration of the organics, the compound 8 can be recovered by filtration as a solid.
- the tosyl acetate compound 8 is converted to the allyl alcohol 9. This is suitably accomplished by reaction with lithium halide and 1 ,8- diazabicyclo[5.4.0]undec-7-ene DBU in dimethylformamide solvent, at elevated temperature, followed by addition of methanol to hydrolyze the acetate group to hydroxyl.
- the product 9 can be recovered by solvent extraction, and concentrated to yield a solid.
- the next step is the coupling of the compound 9 with a selected nucleoside, appropriately protected to ensure coupling through a nuclear nitrogen group to the hydroxyl function of the cyclopentyl nucleus.
- the nucleoside is a protected guanine.
- Suitable protectant groups include CI, OBn and OSi.
- This reaction of compound 9 to produce the entecavir precursor 10 can be accomplished with triphenyl phosphine and diethyl azodicarboxylate DEAD, in THF solvent at temperatures below 0°C. It simply remains to remove the protectant group from the nucleoside portion of the molecule, e.g. by acid hydrolysis. to complete the preparation of the final carbanucleoside compound.
- the reaction was cooled to 5°C and quenched with 2 N aq NaOH to pH 7.
- the aqueous layer was separated and extracted with dichloromethane (2x50 mL).
- the combined organics were dried over sodium sulfate, filtered, and concentrated.
- the resulting semi-solid was dissolved in isopropyl acetate (100 mL) and concentrated to dryness. This was repeated 2 more times.
- the resulting semi-solid was triturated in methyl tert-butyl ether (250 mL), filtered and dried under vacuum to afford 8.1 g of 8 (45%) as a pale yellow solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/698,886 US8658792B2 (en) | 2010-05-31 | 2011-05-30 | Carbanucleoside synthesis and novel intermediate compounds useful therein |
CA2801128A CA2801128A1 (en) | 2010-05-31 | 2011-05-30 | Carbanucleoside synthesis and novel intermediate compounds useful therein |
SI201131341T SI2576565T1 (en) | 2010-05-31 | 2011-05-30 | Carbanucleoside synthesis and novel intermediate compounds useful therein |
EP11789022.8A EP2576565B1 (en) | 2010-05-31 | 2011-05-30 | Carbanucleoside synthesis and novel intermediate compounds useful therein |
CN201180026406.1A CN102933585B (en) | 2010-05-31 | 2011-05-30 | The synthesis of CARBA-nucleosides and the new intermediate wherein used |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2705953A CA2705953C (en) | 2010-05-31 | 2010-05-31 | Carbanucleoside synthesis and intermediate compounds useful therein |
CA2,705,953 | 2010-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011150513A1 true WO2011150513A1 (en) | 2011-12-08 |
Family
ID=45066001
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2011/050324 WO2011150513A1 (en) | 2010-05-31 | 2011-05-30 | Carbanucleoside synthesis and novel intermediate compounds useful therein |
PCT/CA2011/050323 WO2011150512A1 (en) | 2010-05-31 | 2011-05-30 | Process for the synthesis of carbonucleoside and intermediates for use therein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2011/050323 WO2011150512A1 (en) | 2010-05-31 | 2011-05-30 | Process for the synthesis of carbonucleoside and intermediates for use therein |
Country Status (6)
Country | Link |
---|---|
US (2) | US8658792B2 (en) |
EP (2) | EP2576565B1 (en) |
CN (2) | CN102958931B (en) |
CA (4) | CA2705953C (en) |
SI (2) | SI2576556T1 (en) |
WO (2) | WO2011150513A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2536724B1 (en) | 2010-02-16 | 2016-11-23 | ScinoPharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
JP2016196499A (en) * | 2010-07-15 | 2016-11-24 | チェーチャン オーサン ファーマシューティカル カンパニー,リミティド | Synthesis method of entecavir, and intermediate compound thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2705953C (en) | 2010-05-31 | 2018-05-01 | Alphora Research Inc. | Carbanucleoside synthesis and intermediate compounds useful therein |
WO2014000673A1 (en) * | 2012-06-29 | 2014-01-03 | Sunshine Lake Pharma Co., Ltd. | Process for preparation of entecavir |
CN108203435B (en) * | 2016-12-16 | 2020-09-04 | 正大天晴药业集团股份有限公司 | Preparation method of entecavir by using Boc protecting group |
CN112625041A (en) * | 2020-12-25 | 2021-04-09 | 常州博海威医药科技股份有限公司 | Novel preparation method and intermediate of entecavir |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206244A (en) | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
WO2004052310A2 (en) * | 2002-12-11 | 2004-06-24 | Bristol-Myers Squibb Company | Process and intermediates for synthesis entecavir |
CA2639240A1 (en) * | 2008-08-29 | 2010-02-28 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
WO2010074534A2 (en) * | 2008-12-26 | 2010-07-01 | Hanmi Pharm. Co., Ltd. | Novel intermediate and process for preparing entecavir using same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02229192A (en) * | 1989-03-02 | 1990-09-11 | Kohjin Co Ltd | Preparation of purine derivative |
AU2002359732A1 (en) * | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
CN1289510C (en) * | 2003-06-27 | 2006-12-13 | 成都地奥制药集团有限公司 | Antiviral activity possessed compound and preparation method thereof |
CN101235034A (en) * | 2008-02-28 | 2008-08-06 | 陆锦康 | Method for synthesizing entecavir |
US8481728B2 (en) * | 2010-02-16 | 2013-07-09 | Scinopharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
CN101805339B (en) * | 2010-04-12 | 2012-01-11 | 王明 | Entecavir compound preparation method |
US8999246B2 (en) | 2010-05-25 | 2015-04-07 | Exxonmobil Research And Engineering Company | Fluid injection nozzle for fluid bed reactors |
CA2705953C (en) | 2010-05-31 | 2018-05-01 | Alphora Research Inc. | Carbanucleoside synthesis and intermediate compounds useful therein |
CN106928227B (en) | 2010-07-15 | 2020-06-30 | 浙江奥翔药业股份有限公司 | Synthetic method of entecavir and intermediate compound thereof |
-
2010
- 2010-05-31 CA CA2705953A patent/CA2705953C/en not_active Expired - Fee Related
-
2011
- 2011-02-03 CA CA2730622A patent/CA2730622C/en active Active
- 2011-05-30 CA CA2800367A patent/CA2800367A1/en not_active Abandoned
- 2011-05-30 EP EP11789022.8A patent/EP2576565B1/en not_active Not-in-force
- 2011-05-30 WO PCT/CA2011/050324 patent/WO2011150513A1/en active Application Filing
- 2011-05-30 WO PCT/CA2011/050323 patent/WO2011150512A1/en active Application Filing
- 2011-05-30 EP EP11789021.0A patent/EP2576556B1/en not_active Not-in-force
- 2011-05-30 CN CN201180026821.7A patent/CN102958931B/en not_active Expired - Fee Related
- 2011-05-30 SI SI201130588T patent/SI2576556T1/en unknown
- 2011-05-30 CA CA2801128A patent/CA2801128A1/en not_active Abandoned
- 2011-05-30 US US13/698,886 patent/US8658792B2/en active Active
- 2011-05-30 CN CN201180026406.1A patent/CN102933585B/en not_active Expired - Fee Related
- 2011-05-30 US US13/700,259 patent/US9403864B2/en not_active Expired - Fee Related
- 2011-05-30 SI SI201131341T patent/SI2576565T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206244A (en) | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
WO2004052310A2 (en) * | 2002-12-11 | 2004-06-24 | Bristol-Myers Squibb Company | Process and intermediates for synthesis entecavir |
CA2639240A1 (en) * | 2008-08-29 | 2010-02-28 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
WO2010074534A2 (en) * | 2008-12-26 | 2010-07-01 | Hanmi Pharm. Co., Ltd. | Novel intermediate and process for preparing entecavir using same |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2536724B1 (en) | 2010-02-16 | 2016-11-23 | ScinoPharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
JP2016196499A (en) * | 2010-07-15 | 2016-11-24 | チェーチャン オーサン ファーマシューティカル カンパニー,リミティド | Synthesis method of entecavir, and intermediate compound thereof |
EP3483161A1 (en) * | 2010-07-15 | 2019-05-15 | Zhejiang Ausun Pharmaceutical Co., Ltd. | Intermediates used to make entecavir |
Also Published As
Publication number | Publication date |
---|---|
US20130144058A1 (en) | 2013-06-06 |
EP2576565B1 (en) | 2017-08-02 |
EP2576565A4 (en) | 2014-01-01 |
CN102958931B (en) | 2016-04-06 |
US8658792B2 (en) | 2014-02-25 |
CA2730622A1 (en) | 2011-11-30 |
CA2730622C (en) | 2018-07-03 |
US20130066071A1 (en) | 2013-03-14 |
EP2576556A1 (en) | 2013-04-10 |
EP2576556B1 (en) | 2015-08-26 |
CA2705953C (en) | 2018-05-01 |
EP2576565A1 (en) | 2013-04-10 |
CA2800367A1 (en) | 2011-12-08 |
SI2576565T1 (en) | 2018-03-30 |
CA2705953A1 (en) | 2011-11-30 |
CN102933585B (en) | 2015-09-02 |
SI2576556T1 (en) | 2015-10-30 |
CN102958931A (en) | 2013-03-06 |
CA2801128A1 (en) | 2011-12-08 |
US9403864B2 (en) | 2016-08-02 |
CN102933585A (en) | 2013-02-13 |
EP2576556A4 (en) | 2014-01-01 |
WO2011150512A1 (en) | 2011-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2576565B1 (en) | Carbanucleoside synthesis and novel intermediate compounds useful therein | |
JP5202635B2 (en) | Processes and intermediates for the preparation of integrase inhibitors | |
AU2010307562B2 (en) | Novel method for preparing entecavir and intermediate used therein | |
JP5791636B2 (en) | Process for preparing entecavir and its intermediates | |
EP2594569B1 (en) | Entecavir synthesis method and intermediate compound thereof | |
WO2012139455A1 (en) | Intermediates of ticagrelor and method for preparing ticagrelor | |
JP7025064B2 (en) | Stereoselective synthesis of 4'-substituted nucleoside derivatives | |
JP2992575B2 (en) | Method for producing ginkgolide B from ginkgolide C | |
CN110483549B (en) | Preparation method of nitroimidazole pyran antituberculosis drug | |
CN103539773B (en) | Method for preparing ticagrelor key intermediate | |
JPH0859662A (en) | Preparation of n-9-substituted guanine compound | |
EP2149577B1 (en) | New stereospecific method for the preparation of dioxa-bicyclooctane compounds | |
EP2225232B1 (en) | Process for the preparation of substituted 1,3-oxathiolanes | |
US9169277B2 (en) | Epoxidation catalysts | |
CN108912055B (en) | Method for synthesizing antiviral drug cidofovir intermediate and bucyclovir intermediate | |
JP2019501163A (en) | Method for producing HIV integrase inhibitor | |
JP3989997B2 (en) | Method for producing radiosensitizer | |
JP2002510692A (en) | Method for producing purine derivative | |
CN114057792B (en) | Temsirolimus intermediate compounds | |
CN118359621A (en) | Preparation method of intermediates of Li Siwei and Li Siwei and corresponding intermediates of Li Siwei | |
JPH11502826A (en) | Methods for synthesizing nucleoside analogs | |
JP2005527589A (en) | Method for synthesizing β-L-5-fluoro-2 ', 3'-dideoxy-2', 3'-didehydrocytidine (β-L-FD4C) | |
JP3429341B2 (en) | Active vitamin D intermediate | |
CN117659032A (en) | Intermediate of ecteinascidin derivative and synthetic method thereof | |
CN118401509A (en) | Process for preparing (2R, 3S) -2- (benzo [ d ] imidazolylpiperidin-3-ol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180026406.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11789022 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2801128 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13698886 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011789022 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011789022 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11198/DELNP/2012 Country of ref document: IN |